Skip to content

A Prospective Cohort Study Comparing the Efficacy and Safety of PECC, ARMS, and MUSE-TIF Endoscopic Procedures for Gastroesophageal Reflux Disease

A Prospective Cohort Study Comparing the Efficacy and Safety of PECC, ARMS, and MUSE-TIF Endoscopic Procedures for Gastroesophageal Reflux Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119999
Enrollment
Unknown
Registered
2026-03-06
Start date
2026-03-06
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease (GERD), esophagitis, and management of acid-related heartburn symptoms

Interventions

ARMS group:None
MUSE-TIF group:None
PECC group:None

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Meet the diagnostic criteria for GERD; 2.Have endoscopically confirmed Los Angeles grade B or C esophagitis; 3.Are scheduled to undergo elective endoscopic treatment with PECC, ARMS, or MUSE-TIF; 4.Have provided informed consent; 5. Age 18-75

Exclusion criteria

Exclusion criteria: 1.Los Angeles grade D esophagitis or Barrett’s esophagus (long-segment, >3 cm); 2.Esophageal stricture or tumor; 3.Hiatal hernia >3 cm; 4.Severe cardiac, pulmonary, hepatic, or renal insufficiency; 5.History of upper gastrointestinal surgery; 6.Pregnant or lactating women;

Design outcomes

Primary

MeasureTime frame
Medication use;Overall treatment success rate 6 months after surgery;

Secondary

MeasureTime frame
The extent of improvement in GERD symptoms;Quality of life;

Countries

China

Contacts

Public ContactWeiliang Jiang

Shanghai General Hospital

docjiangweiliang@163.com+86 21 6324 0090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026